Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis
Chalmers University of Technology spin out takes a different route to cancer biomarker identification
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.
You may also be interested in...
Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.
Device sales centers are being required to update the government’s product tracking system with sales data under a series of recent changes spurred partly by COVID-19.
In the three months since Brexit, UK medtech stakeholders have seen the beginnings of new regulations, foreign trade plans being put in place, and perhaps new perceptions of medtech’s value.